| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Biology Division, Oak Ridge National Laboratory, and University of Tennessee-Oak Ridge Graduate School of Biomedical Sciences, Oak Ridge, Tennessee 37831
TSP-180 is a Mr 180,000 cell surface protein found on several murine lung carcinomas but not on fibroblast or sarcoma cell lines. Monoclonal antibody 135-13C binds to TSP-180 with high affinity but could not be used to quantitate the protein in tumors and normal tissue (Cancer Res., 41: 34653470, 1981). TSP-180 was purified from a transplantable BALB/c carcinoma (line 1 cells) by immunoaffinity chromatography and used as an immunogen to produce another monoclonal antibody (346-11A) to a different epitope on the molecule. A two-site solid-phase radioimmunoassay for TSP-180 was developed to quantitate TSP-180 in tissue extracts. The assay can detect as little as 3 ng of TSP-180 in samples up to 10 mg of protein. Analyses of several lung carcinoma cell lines confirmed that TSP-180 is present in all (five of five) cell lines ranging from 40 to 800 ng per mg of cell protein extract. Mouse tissues from normal and tumor-bearing mice were analyzed for TSP-180. Values for line 1 tumors growing i.m. were about 70 ng of TSP-180 per mg of protein. Normal tissue from normal and tumor-bearing mice contained low levels of TSP-180 from <0.3 ng/mg of protein for liver to a high of about 11 ng/mg of protein for leg muscle. Finally, small benign urethane-induced adenomas (1 to 2 mm) from BALB/c mice had moderate amounts of TSP-180 (11 ng/mg of protein), while two primary lung adenocarcinomas in the same animals had 20 and 47 ng/mg of protein, respectively, suggesting that TSP-180 expression may increase with increasing cancer of these tumors. Analyses of individual urethane-induced lung tumors from A/J mice showed that 11 of 13 carcinomas had high levels of TSP-180, while only 1 of 6 adenomas had a detectable amount of TSP-180, and that was at a moderate level. Specific quantitation of tumor markers in normal, benign, and malignant lung tissue may be helpful in identifying different levels of gene expression as tumors progress to more malignant states.
1 Research sponsored by the Office of Health and Environmental Research, United States Department of Energy, under Contract DE-AC05-840R21400 with the Martin Marietta Energy Systems, Inc.
2 Recipient of support from Grant CA-09104 from the NIH.
Received 6/11/85. Revised 10/ 8/85. Accepted 10/11/85.
This article has been cited by other articles:
![]() |
T. S. Hiran, J. E. Mazurkiewicz, P. Kreienberg, F. L. Rice, and S. E. LaFlamme Endothelial expression of the {alpha}6{beta}4 integrin is negatively regulated during angiogenesis J. Cell Sci., September 15, 2003; 116(18): 3771 - 3781. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Morena, S. Riccioni, A. Marchetti, A. T. Polcini, A. M. Mercurio, G. Blandino, A. Sacchi, and R. Falcioni Expression of the beta 4 integrin subunit induces monocytic differentiation of 32D/v-Abl cells Blood, June 17, 2002; 100(1): 96 - 106. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Gambaletta, A. Marchetti, L. Benedetti, A. M. Mercurio, A. Sacchi, and R. Falcioni Cooperative Signaling between alpha 6beta 4 Integrin and ErbB-2 Receptor Is Required to Promote Phosphatidylinositol 3-Kinase-dependent Invasion J. Biol. Chem., March 31, 2000; 275(14): 10604 - 10610. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Gimond, C. Baudoin, R. van der Neut, D. Kramer, J. Calafat, and A. Sonnenberg Cre-loxP-mediated Inactivation of the {alpha}6A Integrin Splice Variant In Vivo: Evidence for a Specific Functional Role of {alpha}6A in Lymphocyte Migration but Not in Heart Development J. Cell Biol., October 5, 1998; 143(1): 253 - 266. [Abstract] [Full Text] [PDF] |
||||
![]() |
A Sonnenberg, A. de Melker, A. Martinez de Velasco, H Janssen, J Calafat, and C. Niessen Formation of hemidesmosomes in cells of a transformed murine mammary tumor cell line and mechanisms involved in adherence of these cells to laminin and kalinin J. Cell Sci., January 12, 1993; 106(4): 1083 - 1102. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |